Repligen Corporation
Overview
Repligen Corporation is a biotechnology company headquartered in Waltham, United States, founded in 1981, with 1,001-5,000 employees.
API / Drug Master Files
Repligen Corporation holds 0 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- RG2133(TRIACETYL URIDINE) DRUG SUBSTANCEInactive2002-09-06
- IMMOBLIZED (R) PROTEIN (A) TM, IPA-500Inactive1998-08-26
- IMMOBILIZED PROTEIN A IPA-400HCInactive1998-02-23
- FAST FLOW IMMOBILIZED RECOMBINANT PROTEIN A IN MASSACHUSETTSInactive1990-12-07
- THERAPEUTIC RECOMBINANT PROTEIN AInactive1988-05-20
- IMMOBILIZED RECOMBINANT PROTEIN AInactive1988-05-20
- ULTRAPURE RECOMBINANT PROTEIN AInactive1988-05-20
- FACILITIES LOCATED IN CAMBRIDGE, MAInactive1988-04-22
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Repligen Corporation in our records. PharmaTek screens the full directory against live FDA enforcement data.
Is this Repligen Corporation? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.